Live Breaking News & Updates on Metro international biotech

Stay informed with the latest breaking news from Metro international biotech on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Metro international biotech and stay connected to the pulse of your community

Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study

Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United-states , China , Northwell , Colorado , Dana-farber-cancer-institute , Massachusetts , American , George-clinicals , Roche-genetech , Astrazeneca , Memorial-sloan-kettering-cancer-center , American-society-of-onconephrology

We need more data to help guide the care of patients with cancer who develop kidney related problems

Healthcare staff caring for patients with cancer must have access to high quality and generalizable data regarding the toxicities and repercussions of cancer treatments

Onconephrology, the intersection between oncology and nephrology, is a rapidly evolving field that has gained considerable interest over the past 15 years. Cancer treatments are often highly effective at targeting cancer cells but can lead to unexpected side effects, including acute kidney injury, hypertension, and electrolyte abnormalities. These kidney related toxicities can lead to temporary or permanent discontinuation of potentially lifesaving cancer treatments. Additionally, patients with cancer are living longer and could develop chronic kidney disease after bouts of acute kidney injury, thereby jeopardizing their eligibility for future treatments, in addition to placing them at increased risk of cardiovascular disease and death.1 It is therefore essential that nephrologists, oncologists, and other providers caring for patients with cancer have access to high quality and generalizable data regarding these toxicities and their repercussions.

Despite some progress toward characterizing and understanding the kidney related toxicities associated with cancer treatments, …

S-gupta-sgupta , Shruti-gupta , Astrazeneca , National-institutes-of-health , American-society-of-onconephrology , Ge-healthcare , Global-anemia-council , Metro-international-biotech , National-institute-of-diabetes , American-society , National-institutes , National-institute

iHerb joins Amazon in stopping sales of NMN supplements

iHerb's decision to stop selling NMN supplements in the U.S. is tied to a determination in 2022 by the U.S. Food and Drug Administration.

United-states , Natural-products-association , Alliance-for-natural-health-united-states , Metro-international-biotech , Drug-administration , Walmart , International-biotech , Natural-products , Possibly-big-pharma , Natural-health-united-states ,

FDA, NMN and the case for litigation

Questions raised over the legal status of NMN in dietary supplements are in desperate need of answers, and litigation may offer the quickest path to firm resolution.

United-states , Japan , Mongolia-kingdomway-pharmaceutical , Dietary-supplement-health , Drug-administration , Metro-international-biotech , Federal-food , Cosmetic-act , Education-act , Inner-mongolia-kingdomway-pharmaceutical-limited , Big-pharma

Pharma firm tells FDA NMN can't be sold in dietary supplements

Metro International Biotech has requested the Food and Drug Administration uphold its determination that NMN is excluded from the definition of a dietary supplement product.

United-states , Metro-international-biotech , Drug-administration , Council-for-responsible-nutrition , Natural-products-association , Alliance-for-natural-health-united-states , Natural-health-united-states , Federal-food , Cosmetic-act , Responsible-nutrition , Natural-products

The Friedreich's Ataxia Market Size in the 7MM is anticipated to increase during the study period, 2019–2032, estimates DelveInsight |

The Friedreich's Ataxia Market Size in the 7MM is anticipated to increase during the study period, 2019–2032, estimates DelveInsight |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Neurocrine-biosciences , Healthcare-market-research , Retrotope-inc , Scope-of-the-friedreich-ataxia-market-research , Reata-pharmaceuticals , Veristat-inc , Friedreich-ataxia-market-research , Design-therapeutics-inc , Reata-pharmaceuticals-inc , Metro-international-biotech , List-of-top-selling-market-research

FDA delays substantive response to NMN petition

Citing “competing agency priorities,” the Food and Drug Administration said in a recent letter it has not reached a substantive decision on a citizen petition pertaining to NMN in dietary supplement products.

United-states , China , Chinese , Cara-welch , Alliance-for-natural-health-united-states , Drug-administration , Syncozymes-shanghai-co , Office-of-dietary-supplement-programs , Natural-products-association , Metro-international-biotech , Dietary-supplement-health , Natural-health-united-states

Regulatory expert explores the curious case of NMN

Former Herbalife exec John Venardos examines the curious case of healthy aging ingredient NMN, which U.S. regulators determined is prohibited in supplements.

China , Houston , Texas , United-states , Shanghai , Japan , Baylor-college-of-medicine , Chinese , American , David-sinclair , John-venardos , Chromadex-tru-niagen

ChromaDex raises revenue outlook on strong second quarter

Financial analysts were pleased with ChromaDex's second-quarter results as the healthy aging nutrition company raised its 2023 revenue outlook.

United-states , China , Jeffrey-cohen , Brianna-gerber , Raghuram-selvaraju , Kendall-knysch , Chromadex-tru-niagen , Tru-niagen , Sean-mcgowan , Farmhouse-equity-research , Metro-international-biotech , Chromadex-corp

Regulatory expert explores the curious case of NMN

Former Herbalife exec John Venardos examines the curious case of healthy aging ingredient NMN, which U.S. regulators determined is prohibited in supplements.

United-states , Baylor-college-of-medicine , Texas , Houston , Shanghai , China , Japan , Chinese , American , David-sinclair , Tru-niagen , Chromadex-tru-niagen